Background:

Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients. Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes.

Applications:

ELISA, IHC

Name of antibody:

MLANA

Immunogen:

Synthetic peptide of human MLANA

Full name:

melan-A

Synonyms:

MART1; MART-1

SwissProt:

Q16655

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human esophagus cancer

IHC Recommend dilution:

40-250